Drug delivery systems for local anesthetics

Recent Patents on Drug Delivery and Formulation

Volumn 4, Issue 1, 2010, Pages 23-34

  de Paula, Eneida ^a   Cereda, Cíntia M S ^a   Tofoli, Giovana R ^a   Franz Montan, Michelle ^a   Fraceto, Leonardo F ^b   De Araújo, Daniele R ^c  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^c UNIVERSIDADE FEDERAL DO ABC   (Brazil)

Author keywords

Cyclodextrins; Liposomes; Local anesthetics; Micro and nanoparticles; Polymers; Topical formulations

Indexed keywords

ADRENALIN; ALPHA CYCLODEXTRIN; BENZOCAINE; BETA CYCLODEXTRIN; BIOPOLYMER; BUPIVACAINE; CINCHOCAINE; COCAINE; DIOLEOYLPHOSPHATIDYLCHOLINE; DIPALMITOYLPHOSPHATIDYLCHOLINE; DISTEAROYLPHOSPHATIDYLCHOLINE; DRUG PRESERVATIVE; EMLA; EMOLLIENT AGENT; ETIDOCAINE; GAMMA CYCLODEXTRIN; HYDROXYPROPYLCELLULOSE; LEVOBUPIVACAINE; LIDOCAINE; LIPOSOME; LOCAL ANESTHETIC AGENT; MEPIVACAINE; NANOPARTICLE; PHOSPHATIDYLCHOLINE; POVIDONE; PRILOCAINE; ROPIVACAINE; TETRACAINE; UNINDEXED DRUG; WATER OIL CREAM; CYCLODEXTRIN; DRUG CARRIER;

ANALGESIC ACTIVITY; ARTICLE; COMPLEX FORMATION; CONTROLLED RELEASE FORMULATION; CREAM; DISPERSION; DRUG DELIVERY SYSTEM; EMULSION; GEL; HUMAN; IONIZATION; LIPOSOMAL DELIVERY; LOCAL ANESTHESIA; MICROENCAPSULATION; NONHUMAN; OINTMENT; PARTITION COEFFICIENT; PATENT; PRIORITY JOURNAL; TRANSDERMAL PATCH; VISCOSITY; ANIMAL; CHEMISTRY; INTRADERMAL DRUG ADMINISTRATION; REVIEW; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, TOPICAL; ANESTHETICS, LOCAL; ANIMALS; BIOPOLYMERS; CHEMISTRY, PHARMACEUTICAL; CYCLODEXTRINS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES;

EID: 77449102069     PISSN: 18722113     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221110789957228     Document Type: Article

References (153)

1. Covino BG, Vassalo HG. Local Anesthetics: Mechanisms of action and clinical use. Grune and Stratton: New York 1976; 105.
2. Strichartz GR, Ritchie JM. Local anesthetics. In: Strichartz GR, Ed. Handbook of Experim Pharmacol Springer-Verlag: Berlin 1987.
3. de Jong RH. Local anesthetics. Springfield: Illinois 1994.
4. Grant GJ, Bansinath M. Liposomal delivery systems for local anesthetics. Reg Anesth Pain Med 2001; 26: 61-63.
5. Grant SA. The holygrail: Long-acting local anesthetics and liposomes. Best Prac Res Clin Anesthesiol 2002; 16: 345-352.
6. Rose JS, Neal JM, Kopacz DJ. Extended-duration analgesia: Update on microspheres and liposomes. Reg Anesth Pain Med 2005; 30: 275-285.
7. Araújo DR, Cereda CMS, Brunetto GB, Pinto LMA, Santana MHA, de Paula E. Encapsulation of mepivacaine prolongs the analgesia provided by sciatic nerve blockade in mice. Can J Anaesth 2004; 51: 566-572.
8. Araújo DR, Tsuneda SS, Cereda CMS, et al. Development and pharmacological evaluation of ropivacaine-2-hydroxypropyl-beta- cyclodextrin inclusion complex. Eur J Pharm Sci 2008; 33: 60-71.
9. Langerman L, Grant GJ, Zakowski M, Golomb E, Ramanathan S, Turndorf H. Prolongation of epidural anesthesia using a lipid drug carrier with procaine, lidocaine, and tetracaine. Anesth Analg 1992; 75: 900-905.
10. Mowat JJ, Mok MJ, Macleod BA, Madden TD. Liposomal bupivacaine extended duration nerve blockade using large unilamellar vesicles that exhibit a proton gradient. Anesthesiology 1996; 85: 635-643.
11. Fletcher D, Le Corre P, Guilbaud G, Le Verge R. Antinociceptive effect of bupivacaine encapsulated in poly(D,L)-lactide-co- glycolide microspheres in the acute inflammatory pain model of carrageenin-injected rats. Anesth Analg 1997; 84: 90-94.
12. Boogaerts JG, Lafont ND, Declerq AG, et al. Epidural administration of liposome-associated bupivacaine for the management of postsurgical pain: A first study. J Clin Anesth 1994; 6: 315-320.
13. Kuzma PJ, Kline MD, Calkins MD, Staats PS. Progress in the development of ultra-long-acting local anesthetics. Reg Anesth 1997; 22: 543-551.
14. Gesztes A, Mezei M. Topical anesthesia of the skin by liposome- encapsulated tetracaine. Anesth Analg 1988; 67: 1079-1081.
15. Boogaerts JG, Lafont ND, Luo H, Legros FJ. Plasma concentrations of bupivacaine after brachial plexus administration of liposome-associated and plain solutions to rabbits. Can J Anaesth 1993; 40: 1201-1204.
16. Bucalo BD, Mirikitani EJ, Moy RJ. Comparison of skin anesthetic effect of liposomal lidocaine, nonliposomal lidocaine, and EMLA using 30-minute application time. Dermatol Surg 1998; 24: 537-541.
17. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug-Discov 2005; 4: 145-160.
18. Hung O. Drug transformation: Advances in drug delivery systems. Can J Anaesth 2006; 53:1074-1077.
19. de Paula E, Schreier S. Molecular and physicochemical aspects of local anesthetic-membrane interaction. Braz J Med Biol Res 1996; 29: 877-894.
20. Felnerova D, Viret JF, Glück R, Moser C. Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Curr Opin Biotechnol 2004; 15: 518-529.
21. Araújo DR, Pinto LMA, Braga AFA, de Paula E. Formulações de anestésicos locais de liberação controlada: Aplicações terapêuticas. Rev Bras Anestesiol 2003; 53: 653-661.
22. Viscusi ER. Liposomal drug delivery for postoperative pain management. Reg Anesth Pain Med 2005; 30: 491-496.
23. Malinovsky JM, Benhamou D, Alafandy M, et al. Neurotoxico- logical assessment after intracisternal injection of liposomal bupivacaine in rabbits. Anesth Analg 1997; 85: 1331-1336.
24. Grant GJ, Lax J, Susser L, Zakowski M, Weissman TE, Tundorf H. Wound infiltration with liposomal bupivacaine prolongs analgesia in rats. Acta Anaesthesiol Scand 1997; 41: 204-207.
25. Yu HY, Sun P, Hou WY. Prolonged local anesthetic effect of bupivacaine liposomes in rats. Int J Pharm 1998; 176: 133-136.
26. Grant GJ, Barenholz Y, Piskoun B, Bansinath M, Turndorf H, Bolotin EM. DRV liposomal bupivacaine: Preparation, characteri- zation, and in vivo evaluation in mice. Pharm Res 2001; 18: 336-343.
27. Mashimo T, Ushida I, Pack M, et al. Prolongation of canine epidural anesthesia by liposome encapsulation of lidocaine. Anesth Analg 1992; 74: 827-834.
28. Cereda CMS, Araújo DR, Brunetto GB, de Paula E. Liposomal prilocaine: Preparation, characterization and in vivo evaluation. J Pharm Pharm Sci 2004; 7: 235-240.
29. Lafont ND, Legros MD. Use of liposome associated bupivacaine for the management of a chronic pain syndrome. Anesth Analg 1994; 79: 818.
30. Lafont ND, Legros MD, Boogaerts JG. Use of liposome associated bupivacaine in a cancer pain syndrome. Anaesthesia 1996; 51: 578-579.
31. Grant GJ, Barenholz Y, Bolotin EM, et al. A novel liposomal bupivacaine formulation to produce ultralong-acting analgesia. Anesthesiology 2004; 316:133-137.
32. Legros, F., Ruysschaert, J.-M.: EP233100A1 (1987).
33. Legros, F., Ruysschaert, J.-M.: US5244678 (1993).
34. Camu, F., Alafandy, N., Brasseur, R., Legros, F., Bouffioux, O.: WO9734582 (1997).
35. Camu, F., Brasseur, R., Carlino, S.: WO9742936 (1997).
36. Araújo, D.R., Pinto, L.M.A., Cereda, C.M.S., Brunetto, G.B., Fraceto, L.F., Vanini, R., de Paula, E.: PI3063457 (2003).
37. Kim, S., Kim, T., Murdandi, S.: WO9913865 (1999).
38. Kim, S., Kim, T., Murdandi, S.: US6045824 (2000).
39. Bolotin, E.M., Grant, G.J., Barenholz, Y., Turndorf H., Piskoun, B.: WO0009089 (2000).
40. Bolotin, E.M., Grant, G.J., Barenholz, Y., Turndorf H., Piskoun, B.: US20046696080B1 (2004).
41. Bolotin, E.M., Grant, G.J., Barenholz, Y., Turndorf H., Piskoun, B.: US2008007357944B2 (2008).
42. Barenholz, Y., Garbuzenko, O.: WO2007049279 A2 (2007).
43. Grant, G.J., Bolotin, E.M., Barenholz, Y., Turndorf, H.: WO9949849 (1999).
44. Grant G.J., Bolotin, E.M., Barenholz, Y, Turndorf, M. US20040182830A1 (2004).
45. Grant, G.K., Bolotin, E.M., Barenholz, Y., Turndorf, H.: US20056926905B2 (2005).
46. Narahashi T, Yamada M, Frazier DT. Cationic forms of local anaesthetics block action potentials from inside the nerve membrane. Nature 1969; 223: 748-749.
47. Narahashi T, Frazier DT, Yamada M. The site of action and active form of local anesthetics. I. Theory and pH experiments with tertiary compounds. J Pharmacol Exp Ther 1970; 171: 32-44.
48. Hille B. The pH-dependent rate of action of local anesthetics on the node of Ranvier. J Gen Physiol 1977; 69: 475-496.
49. + channels by local anesthetics. Science 1994; 265: 1724-1728.
50. + channels. Proc Natl Acad Sci USA 1996; 93: 9270-9275.
51. Mezei, M., Gesztes, A.: US4937078 (1990)
52. Lim, J.O.: KR090030A (2001).
53. Lim, J.O., Baek, W.Y., Kim, D.W.: WO019403A1 (2001).
54. Huebner, S.: DE19938800A1 (2001).
55. Patel, M.P.: US20030104046 A1 (2003).
56. Smith, S.C., Czerwinski, J., Davies, M., Moak, D., Ramey, B.: US20040228803A1 (2004).
57. Cevc, G.: US20070031483A1 (2007).
58. Silva, A.R., Franz-Montan, M., Groppo, F.C., Volpato, M.C., Ranali, J., Fraceto, L.F., de Paula, E.: WO2008138089A2 (2008).
59. Tiwary AK, Sapra B, Jain S. Innovations in transdermal drug delivery: Formulations and techniques. Recent Pat Drug Deliv Formul 2007; 1: 23-36.
60. Blaso, J.D.: US2187597 (1940).
61. Reasemberg, J.R.: US2628182 (1953).
62. Stone, R.A.: US3322624 (1967).
63. Kaplan, C.: US4052513 (1977).
64. Stone, R.: US4344965 (1982).
65. Broberg, B.F.J., Evers, H.C.A.: US4562060 (1985).
66. Busciglio, J.A.: US4748022 (1988).
67. Walele, I.I., Scarangella, N.J., Ansaldi, A., Andrews, A.M., Syed, S.A.: US5271930 (1993).
68. Reuter, G.L., Harrison, M.M., Coons, M.E.: US5446063 (1995).
69. Holden, P., Sandbank, B.M.: US5484603 (1996).
70. Henry, R.A.: US5534242 (1996).
71. Ernst, A.A: US5585398 (1996).
72. Cohen, P.D., Haight, C.: US5558914 (1996).
73. Caldwell, L.J., Galer, B.S.: US5667799 (1997).
74. Castillo, J.G.: US5993836 (1999).
75. Luriya, E., Luriya, L.: WO9922703A1 (1999).
76. Courmont, C., Raynaud, J.: FR2783715A1 (2000).
77. Fotinos, S., Tsardaka, E., Koborozos, G.: WO0113955A1 (2001).
78. Fotinos, S., Tsardaka, E., Koborozos, G.: WO2004091553A2 (2004).
79. Won Jun, H., Kang, L.: US20016299902B1 (2001).
80. Wepfer, S.: WO141550A2 (2001).
81. Samuels, P., Sweeney, D.: WO54679A2 (2001).
82. Bello, G.P., Packman E.W.: US20016277401B1 (2001).
83. Zhang, J.: W0122907A1 (2001).
84. Inagi, T., Mada, A.: US20026429228B1 (2002).
85. Luo, E.C., Gricenko, N.T., Hsu, T.: US20020197284A1 (2002).
86. Luo, E.C., Gricenko, N.T., Hsu, T.: US20040086556A1 (2004).
87. Cleary, G.W., Mudumba, S., Parandoosh, S.,Cleary, C.J., Birudaraj, R., Park, P.: US20030027833A1 (2003).
88. Mueller, B., Christiansen, C.: WO055465A1 (2003).
89. Patel, P.M., Lemko, M.: WO059320A1 (2003).
90. Bouffard Fita, F.: WO2004110423A1 (2004).
91. Liedtke, R. K.: DE4027685A1 (2005).
92. Castillo, J.G.: US20056894078B2 (2005).
93. Blanco, A.: US20070003627A1 (2007).
94. Sheil, M., Giffard, A., Olsson, C.R. WO2006096914-A1 (2006).
95. Sand, B.J., Babich, M., Haghighi, A.Z.: WO2007103555A2 (2007).
96. Wepfer, S., Wepfer, S.T.: US20077273887B1 (2007).
97. Brown, M.B., Jones, S.A.: WO2007031753A2 (2007).
98. Aberg, G.A.K., Johnson, K.A.: WO2007038325A2 (2007).
99. Aberg, A.K.G., Johnson, K.A.: WO2008088756A1 (2008).
100. Myers, M., Reginald, P.W.: US20080241243A1 (2008).
101. Fuisz, R.C., Fuisz, J.M., Myers, G.L., Yang, R.K., Sanghvi, P.P.: WO2008100375 (2008).
102. Reiz GME, Reiz SLA. EMLA - a eutectic mixture of local anaesthetics for topical anaesthesia acta anesthest. Scand 1982; 26: 596-598.
103. Cleary, G.W., Mudumba, S., Parandoosh, S., Birudaraj, R., Park, P.: US20024839175 (2002).
104. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins. Drug solubilization and stabilization. J Pharm Sci 1996; 85: 1017-1025.
105. Loftsson T, Hreindóttir D, Másson M. Evaluation of cyclodextrins solubilization of drugs. Int J Pharm 2005; 302: 18-28.
106. Loftsson T, Hreindóttir D, Másson M. The complexation efficiency. J Incl Phenom Macrocycl Chem 2007; 57: 545-552.
107. Loftsson T, Duchêne D. Cyclodextrins and their pharmaceutical applications. Int J Pharm 2007; 329: 1-11.
108. Szejtli J. Cyclodextrin and their inclusion complexes. Academia Kiado: Budapest, Hungary 1982.
109. Szejtli J. Introduction and general overview of cyclodextrin chemistry. Chem Rev 1998; 98: 1743-1753.
110. Duchêne D. Cyclodextrins and their industrial uses. Ed. de Sante, Paris 1987.
111. Rajewski RA, Stella VJ. Pharmaceutical applications of cyclodextrins. in vivo drug delivery. J Pharm Sci 1996; 85: 1142-1169.
112. Irie T, Uekama, K. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J Pharm Sci 1997; 86: 147-162.
113. Hirayama F, Uekama K. Cyclodextrin-based controlled drug- release system. Adv Drug Deliv Rev 1997; 36: 125-141.
114. Davis ME, Brewster ME. Cyclodextrin-based pharmaceutics: past, present and future. Nat Rev Drug Discov 2004; 3: 1023-1035.
115. Carpenter TO, Gerloczy A, Pitha J. Safety of parenteral hydroxypropyl -cyclodextrin. J Pharm Sci 1995; 84: 222-225.
116. Gould S, Scott RC. 2-Hydroypropyl-β-cyclodextrin (HP-β-CD): A toxicology review. Food Chem Toxicol 2005; 43: 1451-1459.
117. Dollo G, Thompson DO, Le Corre P, Chevanne, F, Le Verge R. Inclusion complexation of amide-typed local anesthetics with - cyclodextrin and its derivatives. III. Biopharmaceutics of bupivacaine-SBE7- -CD complex following percutaneous sciatic nerve administration in rabbits. Int J Pharm 1998; 164: 11-19.
118. Dollo G, Le Corre P, Freville JC, Chevanne F, LeVerge R. Biopharmaceutics of local anesthetic-cyclodextrin complexes following loco-regional administration. Ann Pharm Fr 2000; 58; 425-432.
119. Estebe JP, Ecoffey C, Dollo G, Le Corre P, Chevanne F, Le Verge R. Bupivacaine pharmacokinetiocs and motor blockade following epidural administration of the bupivacaine- sulfobutylether -7-- cyclodextrin complex in sheep. Eur J Anaesthesiol 2002; 19: 308-310.
120. Dollo G, Le Corre P, Chevanne F, Le Verge R. Inclusion complexation of amide-typed local anesthetics with -cyclodextrin and its derivatives. I. Physicochemical characterization. Int J Pharm 1996; 131: 165-174.
121. Dollo G, Le Corre P, Chevanne F, Le Verge R. Inclusion complexation of amide-typed local anesthetics with -cyclodextrin and its derivatives. II. Evaluation of affinity constants and in vitro transfer rate constants. Int J Pharm 1996; 136: 219-228.
122. Fréville JC, Dollo G, Le Corre P, Chevanne F, Le Verge R. Controlled systemic absorption and increased anesthetic effect of bupivacaine following epidural administration of bupivacaine- hydroxypropyl -cyclodextrins complex. Pharm Res 1996; 13: 1576-1580.
123. Moraes CM, Abrami P, Araújo DR, et al. Characterization of lidocaine: Hydroxypropyl- -cyclodextrin inclusion complex. J Incl Phenom Macrocycl Chem 2007a; 57: 313-316.
124. Moraes CM, Abrami P, de Paula E, Braga AFA, Fraceto LF. Study of the interaction between S(-) bupivacaine and 2-hydroxypropyl- beta-cyclodextrin. Int J Pharm 2007; 331: 99-106.
125. Araújo DR, Fraceto LF, Braga AFA, de Paula E. Drug delivery systems for racemic BPV (S50-R50) and BPV enantiomeric mixture (S75-R25): Cyclodextrins complexation effects on sciatic nerve blockade in mice. Rev Bras Anestesiol 2005; 55: 316-328.
126. Araújo DR, Moraes CM, Fraceto LF, Braga AFA, de Paula E. Complexation of 50% enantiomeric excess (S75-R25) bupivacaine with cyclodextrins and spinal block anesthesia in rats. Rev Bras Anestesiol 2006; 56: 495-506.
127. Karashima K, Kasaba T, Taniguchi M, Irikura M, Irie T, Takasaki M. Plasma levobupivacaine concentrations following epidural administration of levobupivacaine conjugated with or without maltosyl-beta-cyclodextrin. Masui 2006; 55: 1382-1386.
128. Karashima K, Taniguchi M, Nakamura T, et al. Prolongation of intrathecal and sciatic nerve blocks using a complex of levobupivacaine with maltosyl-beta-cyclodextrin in rats. Anesth Analg 2007; 104: 1121-1128.
129. Defaye J, García-Fernández JM, Ortiz Mellet C. Pharmaceutical use of cyclodextrines: Perspectives for drug targeting and control of membrane interactions. Ann Pharm Fr 2007; 65: 33-49.
130. Stella VJ, He Q. Cyclodextrins. Toxicol Pathol 2008; 36: 30-42.
131. Carpenter TO, Pettifor JM, Russell RM, et al. Severe hypervitaminosis A in siblings: Evidence of variable tolerance to retinol intake. J Pediatr 1987; 111: 507-512.
132. Seiller KU, Szathmary S, Huss HJ, Coster De R, Junge W. Safety profile and intravenous tolerance of HP- -CD after increasing single dose. In: Duchene D, Ed. Minutes of the 5th Int Symp Cyclodextrins. Ed de Sante, Paris 1990.
133. Thompson DO. Cyclodextrins-enabling excipients: Their present and future use in pharmaceuticals. Crit Rev Ther Drug Carr Syst 1997; 14: 1-104.
134. Brewster ME, Loftsson T. Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliv Rev 2007; 59: 645-666.
135. Borgbjerg, F.: WO9505198 (1995).
136. Hiji, Y.: EP0838225A2 (1998).
137. Moldenhauer, J.P.: DE10033059A1 (2002).
138. Pinto, L.M.A., Araújo, D.R., de Jesus, M.B., Vanini, R., Lino, A.C.S., Takahata, Y., de Paula, E.: PI3039846 (2003).
139. Fessi H, Puiseiux F, Devissaguet J-P, Ammoury N, Benita S. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int J Pharm 1989; 55: 1-4.
140. Corre PL, Guevello PL, Gajan V, Chevanne F, Verge RL. Preparation and characterization of bupivacaine-loaded polylactide and polylactide-coglycolide microspheres. Int J Pharm 1994; 107: 41-49.
141. Curley J, Castillo J, Hotz J, et al. C. Prolonged regional nerve blockade. Injectable biodegradable bupivacaine/polyester microspheres. Anesthesiology 1996; 84:1401-1410.
142. Polakovic M, Gorner T, Gref R, Dellacherie E. Lidocaine loaded biodegradable nanospheres II. Modelling of drug release. J Control Release 1999; 60: 169-177.
143. Gorner T, Gref R, Michenor D, Sommer F, Tran MN, Dellacherie E. Lidocaine-loaded biodegradable nanospheres. Optimization of the drug incorporation into the polymer matrix. J Control Release 1999; 57: 259-268.
144. Kohane DS, Smith SE, Louis DN, et al. Prolonged duration local anesthesia from tetrodotoxin-enhanced local anesthetic microspheres. Pain 2003; 104: 415-421.
145. Blanco MD, Bernardo MV, Sastre RL, Olmo R, Muniz E, Teijón JM. Preparation of bupivacaine-loaded poly(-caprolactone) microspheres by spray drying: Drug release studies and biocompatibility. Eur J Pharm Biopharm 2003; 55: 229-236.
146. Klose D, Siepmann F, Elkharraz K, Krenzlin S, Siepmann J. How porosity and size affect the drug release mechanisms from PLGA- based microparticles. Int J Pharm 2006; 314: 198-206
147. Montanari L, Cilurzo F, Selmin F, et al. Poly(lactide-co-glycolide) microspheres containing bupivacaine: Comparison between gamma and beta irradiation effects. J Control Release 2003; 90: 281-290.
148. Hu, Z., Lu, X., Gao, J., Ponder, B., John, J. Moro, D.G.: WO01022910A1 (2001).
149. Vaugn, W.M., Van Hamont, J.E., Setterstrom, J.A.: US20016217911B1 (2001).
150. Sawhney, A.S.: US20036632457 B1 (2003).
151. Liggins, R.T., Toleikis, P.M., Guan, D.: WO2006002365A2 (2006).
152. Ramaswami, B., Patil, M.R.: WO20081100534 A1 (2008).
153. Domb, A.J.: US5188837 (1993).